This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C. The workshop is free to attend and available to all. More information on the Scientific Workshop can be found here and registration for the live-stream can be found here.
Importantly, the Hub is intended to establish a new model within FDA, which leverages cross-Agency expertise in providing guidance and conducting reviews for products for rare disease populations. By Sarah Wicks & James E. Valentine & Frank J. those reviewed by the CDER Division of Rare Diseases and Medical Genetics).
Brevig, Senior Regulatory Device and Biologics Expert — On October 26, 2022, US Pharmacopeia (USP) Biologics Stakeholder Forum held a workshop on “Collaborating to solve CMC challenges and support efficient development of lentiviral-mediated CART cell therapies.” Opportunity for feedback from FDA if provided pre-BLA. By Holly N.
USP/BIOPHORUM Workshop on Continuous Manufacturing of Biologics Trudy Patterson Fri, 07/07/2023 - 08:45 Features July / August 2023 USP/BIOPHORUM Workshop on Continuous Manufacturing of Biologics John F. This article summarizes trends from the workshop and ponders next steps. Biotechnology and Bioengineering (2023): 1–6.
Schwartz — FDA recently published a Federal Register (FR) Notice [ Docket No. FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies.
SMi Reports: An exclusive interview with María José López Barragán, Founder, Barragan BioConsulting, formerly CMC Product Quality Reviewer, FDA, who will be speaking at the 3rd Annual Pharmaceutical Microbiology East Coast Conference released. Workshop: October 30th, 2020. María José (Pepa) Lopez Barragán is a former U.S.
These questions have pitted lawmakers against the FDA and venture capitalists against the Coalition for Health AI (CHAI) and its Big Tech partners. Industry bodies, investors, Congress, and federal agencies are unable to agree on which voluntary AI validation frameworks will help ensure that patients are safe.
Both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have endorsed a statement calling for international collaboration on integrating real-world evidence (RWE) into regulatory decision-making.
In light of the urgent public health need to facilitate and expedite access to naloxone, FDA is implementing this Guidance immediately without prior public comment. Because naloxone is a prescription drug, its distribution is subject to the requirements of the Drug Supply Chain Security Act (DSCSA).
This three-day summit will feature numerous presentations, workshops and networking opportunities featuring government officials, drug pricing and reimbursement lawyers and experts and industry leaders. FDA Law Blog readers can receive a 10% discount off the conference registration price. A complete agenda is available here.
The US Food and Drug Administration (FDA) has decided to fast-track psilocybin for depression, with full support from President Biden’s administration. 6 It also states that a multi-stakeholder workshop is being planned for Q3/Q4 of 2023, which will focus on promoting the development of psychedelics that address unmet medical needs.
SMi Reports: SMi Group have made the decision due to travel restrictions to open the conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on October 28 and 29 2020. Workshop B- Mycoplasma testing by anyone, anywhere and anytime! Workshops: October 30th, 2020.
The Computer Software Assurance (CSA) concepts published as draft guidance by the FDA and that are already embedded in GAMP ® 5 Second Edition will be discussed in detail. Link them through a TM, otherwise the FDA will give you a 483!” Will CSA be accepted outside of the US? What about for something that is not a Medical Device?
Lenz, Principal Medical Device Regulation Expert — FDA’s Center for Devices and Radiological Health (CDRH) recently partnered with the Digital Medicine Society (DiMe) to host a two-day workshop to help advance the use of patient-generated health data (PGHD) to support improved clinical trials, medical device development, and regulatory science.
Drug shortages have been a scourge for FDA , both as they negatively affect consumers and FDA’s reputation. From that lack of detail, it would appear that FDA thinks of Good Manufacturing Practice (cGMP) compliance as a timeless and ecumenical pursuit, following the well-worn path laid out in its now-18 year old guidance.
Brevig, Senior Regulatory Device and Biologics Expert — In January 2023, FDA published a paper summarizing its lessons learned from two pilot Quality Management Maturity (QMM) Pilot Programs, such as best practices for conducting QMM assessments and developing the QMM scoring system.
This blog provides an update on the DHT-related PDUFA VII goals that were targeted for completion in the first two quarters of FDA’s Fiscal Year (FY) 2023, including: By the end of Q2 FY 2023, FDA will establish a DHT framework document to guide the use of DHT-derived data in regulatory decision-makings for drugs and biological products.
Cato — On May 2nd, FDA released a new draft guidance with recommendations for decentralized clinical trials (DCTs) for drugs, biologics, and devices. This draft guidance builds on recommendations that FDA initially developed early in 2020, in response to the COVID-19 challenges (see our blog post on these recommendations here ).
This year, Dr. Jennifer Maguire joined from FDA CDER’s Office of Quality Surveillance (OQS) to provide a keynote presentation on Quality Management Maturity (QMM) and the FDA’s ongoing QMM program development. Furthermore, any QMM rating program will be voluntary whereas Quality Metrics are considered mandatory under FDA regulations.
Thomas O’Connor, PhD, Deputy Director, Office of Testing and Research, FDA will round out the session by highlighting regulatory viewpoints on advanced manufacturing initiatives, including his sharing of output from CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative. Dennis Powers. G-CON Manufacturing.
As previously m entioned , sponsors can interact with FDA in the town hall by submitting questions in advance or by asking a question live during the meeting. The Agency repeatedly stated and strongly recommends sponsors engage with FDA prior to submitting the IND. The workshop is also discussed in Cell & Gene here and here.
Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. Turbocharge the Development of the Best-In-Class Kinase Inhibitor Products, to Enhance Specificity, Overcome Resistance to Deliver Safe & Durable Clinical Responses.
Invest in Continuous Learning : Hosting regular training sessions and workshops keeps teams updated on the latest digital trends, compliance regulations, and AI-powered marketing innovations. When combined with AI-powered analytics, programmatic advertising ensures that marketing budgets are used efficiently to generate maximum ROI.
The NDA for Abicipar pegol, which utilizes DARPin technology was rejected by the FDA secondary to concerns of inflammation with the 2 mg dose”. Brolucizumab was approved, but it is associated with a small risk of occlusive vasculitis which can lead to profound, irreversible vision loss. Therefore, brolucizumab has not been widely adopted.
Compounding laws and regulations are a patchwork of rules and guidelines created by the FDA, USP, and state boards of pharmacy. While states can create their own rules, according to FDA guidelines, semaglutide and tirzepatide can be compounding because they are on the FDA shortage list.
™ started in 2015 at the ISPE Germany/Austria/Switzerland (D/A/CH) “Plug and Produce” workshop in Basel, Switzerland. ™, driven by the recognition that digital transformation offers a big chance to finally realize the US FDA’s Pharmaceutical Quality for the 21st Century Initiative to the full extent. to a pharma-specific Pharma 4.0™
The opening keynote will feature Brook Higgins from the FDA and focus on the critical role of environmental monitoring and preventative steps to take for a strong sterility assurance program to reduce positive sterility tests. How should the new requirements around aseptic process simulations (APS), also known as media fills, be implemented?
USA The FDA established the Emerging Technology Program (ETP) in 2014 and has actively promoted the program 8. A final report will be provided as the basis for an ISPE workshop, with recommendations subsequently published in Pharmaceutical Engineering and other trade publications. 22 June 2023. link] 16 US Food and Drug Administration.
As the Executive Fellow on the Engagement, Education and Convening team, I’m excited to deliver guest lectures about PQA and healthcare quality to professional students, facilitate educational workshops and webinars, and precept fourth-year pharmacy students this fall. Joint Commission, CMS, URAC, FDA).
In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. The FDA’s action plan. Thus, FDA funding could be what is needed on this front, says Cudkowicz.
Main Conference: April 25 – 26, 2022 | Workshops: April 27, 2022. Guest FDA Speaker: John Barr Weiner, Associate Director for Policy and Product Classification Office, Office of Combination Products FDA. . POST CONFERENCE WORKSHOP A: EU MDR 2017/745 Article 117 Requirements. SMi’s 9th Annual Conference.
Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision about whether to participate in a clinical trial, and what kind of treatment effects would be most meaningful to them?
Working in both marketing and advertising campaigns but also market research, strategic planning, workshop facilitation. Everyone of course knows the benefit of accelerating the trial and that the drug gets evaluated quicker, gets submitted to the FDA quicker and gets approved quicker.
Livornese — Last month, Congress took a big step towards improving clinical trial diversity by requiring sponsors of most drug and device clinical studies to submit a diversity action plan when they submit key trial documents to the Food and Drug Administration (FDA). This guidance was finalized in 2020. by the end of 2023).
The first keynote speaker was Michael Kopcha, PhD, RPh, Director of the Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), US FDA. The US FDA monitors quality, and Kopcha traced changes in regulation of quality over the years. FDA Activities in Support of Quality. Tue, 11/01/2022 - 06:49.
7 A critical feature of the ETP is representation from all relevant FDA quality assessment and inspection programs, from early engagement with stakeholders through application submission and assessment. 13 An FDA-authored paper indicating support for the implementation of CM using science- and risk-based approaches followed soon thereafter.
The session included regulators from the European Medicines Agency (EMA), the UK Medicines & Healthcare Products, Regulatory Agency (MHRA), the Spanish Agency of Medicines and Medical Products (AEMPS) and the US Food and Drug Administration (FDA). Rosa stressed that FDA was seeing a great deal of silo behavior in large companies.
Project RiskSurve from FDA: a project to create a comprehensive site surveillance model consolidating data from different dimensions: what are the first learnings? Brooke Higgins, Senior Policy Advisor for the Global Compliance Branch 3, FDA has chosen the following title for her presentation: “Testing Positive….
In December 2021, the US FDA issued a cross-center draft guidance with recommendations on the use of digital health technology tools (DHTTs) to acquire data remotely from participants in clinical investigations for medical products. Table 3: Example classification of DHTs. .
In December 2021, the US FDA issued a cross-center draft guidance with recommendations on the use of digital health technology tools (DHTTs) to acquire data remotely from participants in clinical investigations for medical products. Table 3: Example classification of DHTs. .
Its Pharmaceutical Education & Research Center (PERC) is a US Food and Drug Administration (FDA)-registered, cGMP-compliant, single-source CRO equipped with the latest equipment and technologies, for most dosage forms, found in the pharmaceutical industry. As automation and Pharma 4.0
FDA (US Food and Drug Administration). Brendan Cuddy , EMA, Stelios Tsinontides, US FDA, and Karl Cogan, (HPRA), discussed the International Coalition of Medicine Regulatory Authority (ICMRA)’s Regulatory Collaboration Pilot projects. Brendan Cuddy. Lead Scientific Officer. Karl Cogan. Executive Assistant To CEO. Deborah Smith.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
59 
Let's personalize your content